

# company announcement

## Trading in Novo Nordisk shares by board members, executives and associated persons

**Bagsværd, Denmark, 7 August 2025** — This company announcement discloses the data of the transaction(s) made in Novo Nordisk shares by the company's board members, executives and their associated persons in accordance with Article 19 of Regulation No. 596/2014 on market abuse.

The company's board members, executives and their associated persons have reported the transactions to Novo Nordisk and have given Novo Nordisk power of attorney on their behalf to publish trading in Novo Nordisk shares by the company's board members, executives and their associated persons.

Please find below a statement of such trading in shares issued by Novo Nordisk.

<b>1</b>	<b>Details of the person discharging managerial responsibilities/person closely associated</b>							
a)	Name of the Board member/Executive/Associated Person	Martin Holst Lange						
<b>2</b>	<b>Reason for the notification</b>							
a)	Position/status	Executive Vice President						
b)	Initial notification/Amendment	Initial notification						
<b>3</b>	<b>Details of the issuer</b>							
a)	Name	Novo Nordisk A/S						
b)	LEI	549300DAQ1CVT6CXN342						
<b>4</b>	<b>Details of the transaction(s)</b>							
a)	Description of the financial instrument, type of instrument, Identification code	Shares  Novo Nordisk B DK0062498333						
b)	Nature of the transaction	Sale of shares						
c)	Price(s) and volume(s)	<table border="1"> <thead> <tr> <th>Price(s)</th> <th>Volume(s)</th> </tr> </thead> <tbody> <tr> <td>DKK 316.75</td> <td>74</td> </tr> <tr> <td></td> <td></td> </tr> </tbody> </table>	Price(s)	Volume(s)	DKK 316.75	74		
Price(s)	Volume(s)							
DKK 316.75	74							
d)	Aggregated information <ul style="list-style-type: none"> <li>Aggregated volume</li> <li>Price</li> </ul>	74 shares DKK 23,439.50						
e)	Date of the transaction	2025-08-07						
f)	Place of the transaction	(CGET) CITIGROUP GLOBAL MARKETS EUROPE AG - EMEA TRADING						
<b>1</b>	<b>Details of the person discharging managerial responsibilities/person closely associated</b>							
a)	Name of the Board member/Executive/Associated Person	Martin Holst Lange						

<b>2</b>	<b>Reason for the notification</b>							
a)	Position/status	Executive Vice President						
b)	Initial notification/Amendment	Initial notification						
<b>3</b>	<b>Details of the issuer</b>							
a)	Name	Novo Nordisk A/S						
b)	LEI	549300DAQ1CVT6CXN342						
<b>4</b>	<b>Details of the transaction(s)</b>							
a)	Description of the financial instrument, type of instrument, Identification code	Shares  Novo Nordisk B DK0062498333						
b)	Nature of the transaction	Sale of shares						
c)	Price(s) and volume(s)	<table border="1"> <thead> <tr> <th>Price(s)</th> <th>Volume(s)</th> </tr> </thead> <tbody> <tr> <td>DKK 316.48</td> <td>13,950</td> </tr> <tr> <td></td> <td></td> </tr> </tbody> </table>	Price(s)	Volume(s)	DKK 316.48	13,950		
Price(s)	Volume(s)							
DKK 316.48	13,950							
d)	Aggregated information <ul style="list-style-type: none"> <li>• Aggregated volume</li> <li>• Price</li> </ul>	13,950 shares DKK 4,414,898.43						
e)	Date of the transaction	2025-08-07						
f)	Place of the transaction	Outside a trading venue						

*Novo Nordisk is a leading global healthcare company founded in 1923 and headquartered in Denmark. Our purpose is to drive change to defeat serious chronic diseases built upon our heritage in diabetes. We do so by pioneering scientific breakthroughs, expanding access to our medicines and working to prevent and ultimately cure disease. Novo Nordisk employs about 78,400 people in 80 countries and markets its products in around 170 countries. Novo Nordisk's B shares are listed on Nasdaq Copenhagen (Novo-B). Its ADRs are listed on the New York Stock Exchange (NVO). For more information, visit [novonordisk.com](https://www.novonordisk.com), [Facebook](#), [Instagram](#), [X](#), [LinkedIn](#) and [YouTube](#).*

## Contacts for further information

### Media:

**Ambre James-Brown**

+45 3079 9289

[abmo@novonordisk.com](mailto:abmo@novonordisk.com)

**Liz Skrbkova (US)**

+1 609 917 0632

[lzsk@novonordisk.com](mailto:lzsk@novonordisk.com)

### Investors:

**Jacob Martin Wiborg Rode**

+45 3075 5956

[jrde@novonordisk.com](mailto:jrde@novonordisk.com)

**Sina Meyer**

+45 3079 6656

[azey@novonordisk.com](mailto:azey@novonordisk.com)

**Max Ung**

+45 3077 6414

[mxun@novonordisk.com](mailto:mxun@novonordisk.com)

**Christoffer Sho Togo Tullin**

+45 3079 1471

[cftu@novonordisk.com](mailto:cftu@novonordisk.com)

**Alex Bruce**

+45 3444 2613

[axeun@novonordisk.com](mailto:axeun@novonordisk.com)

**Frederik Taylor Pitter**

+1 609 613 0568

[fptr@novonordisk.com](mailto:fptr@novonordisk.com)